Advertisement

CEN Case Reports

, Volume 8, Issue 2, pp 101–105 | Cite as

Fibrosing cholestatic hepatitis in a kidney transplant recipient with hepatitis C virus

  • Takahiro ShinzatoEmail author
  • Taro Kubo
  • Toshihiro Shimizu
  • Koji Nanmoku
  • Takashi Yagisawa
Case Report

Abstract

Fibrosing cholestatic hepatitis (FCH) is a fatal disorder that presents as a progressive deterioration of liver function over a period of several weeks to several months. It is caused by the direct cytotoxic effect of the over-expression of viral antigens on hepatocytes in immunosuppressed patients. Our patient was a 59-year-old man with hepatitis C virus (HCV) infection of genotype 2a who had suffered from end-stage renal disease due to diabetic nephropathy and underwent kidney transplantation. His serum total bilirubin levels gradually increased to 20 mg/dl and liver atrophy progressed during several weeks after kidney transplantation, which was initially difficult to distinguish from drug-induced liver injury. We diagnosed the condition as FCH on the basis of pathological findings and increased HCV viral load, and treated the patient with Glecaprevir/Pibrentasvir. However, the patient died of refractory hemorrhagic gastric ulcer and liver failure. Currently, it is possible to treat infections of all genotypes of HCV, even with end-stage renal disease, with direct acting antivirals. Furthermore, it is preferable to treat HCV before kidney transplantation considering the risk of FCH due to immunosuppressive therapy.

Keywords

Fibrosing cholestatic hepatitis Kidney transplantation Hepatitis C 

Notes

Acknowledgements

We would like to thank Professor Norio Isoda, department of hepatology, Jichi Medical University Hospital, Japan, for his great contribution.

Compliance with ethical standards

Conflict of interest

All the authors have declared no competing interest.

Human and animal rights

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

Written informed consent obtained from the patient.

References

  1. 1.
    O’Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, Portmann B, Alexander GJ, Williams R. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992;14(1):104–11.CrossRefGoogle Scholar
  2. 2.
    Davies SE, Portmann BC, O’Grady JG, Aldis PM, Chaggar K, Alexander GJ, Williams R. Hepatic histological findings after transplantation for chronic hepatitis B infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991;13(1):150–7.CrossRefGoogle Scholar
  3. 3.
    Benner KG, Lee RG, Keeffe EB, Lopez RR, Sasaki AW, Pinson CW. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology. 1992;103(4):1307–12.CrossRefGoogle Scholar
  4. 4.
    Phillips MJ, Cameron R, Flowers MA, Blendis LM, Greig PD, Wanless I, Sherman M, Superina R, Langer B, Levy GA. Post-transplant recurrent hepatitis B viral liver disease. Viral-burden, steatoviral, and fibroviral hepatitis B. Am J Pathol. 1992;140(6):1295–308.Google Scholar
  5. 5.
    Lau JY, Bain VG, Davies SE, O’Grady JG, Alberti A, Alexander GJ, Williams R. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology. 1992;102(3):956–62.CrossRefGoogle Scholar
  6. 6.
    Zylberberg H, Carnot F, Mamzer MF, Blancho G, Legendre C, Pol S. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. Transplantation. 1997;63(1):158–60.CrossRefGoogle Scholar
  7. 7.
    Lucey MR, Graham DM, Martin P, Di Bisceglie A, Rosenthal S, Waggoner JG, Merion RM, Campbell DA, Nostrant TT, Appelman HD. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut. 1992;33(10):1390–6.CrossRefGoogle Scholar
  8. 8.
    Furuta K, Takahashi T, Aso K, Hoshino H, Sato K, Kakita A. Fibrosing cholestatic hepatitis in a liver transplant recipient with hepatitis C virus infection: a case report. Transpl Proc. 2003;35(1):389–91.CrossRefGoogle Scholar
  9. 9.
    Rosenberg PM, Farrell JJ, Abraczinskas DR, Graeme-Cook FM, Dienstag JL, Chung RT. Rapidly progressive fibrosing cholestatic hepatitis-hepatitis C virus in HIV coinfection. Am J Gastroenterol. 2002;97(2):478–83.CrossRefGoogle Scholar
  10. 10.
    Boletis JN, Delladetsima JK, Makris F, Theodoropoulou H, Vgenopoulou S, Kostakis A, Hatzakis A. Cholestatic syndromes in renal transplant recipients with HCV infection. Transpl Int. 2000;13(Suppl 1):375–9.CrossRefGoogle Scholar
  11. 11.
    Siddiqui AR, Abbas Z, Luck NH, Hassan SM, Aziz T, Mubarak M, Naqvi SA, Rizvi SA. Experience of fibrosing cholestatic hepatitis with hepatitis C virus in kidney transplant recipients. Transpl Proc. 2012;44(3):721–4.CrossRefGoogle Scholar
  12. 12.
    Muñoz De Bustillo E, Ibarrola C, Colina F, Castellano G, Fuertes A, Andrés A, Aguado JM, Rodicio JL, Morales JM. Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant recipients. J Am SocNephrol. 1998;9(6):1109–13.Google Scholar
  13. 13.
    Delladetsima JK, Boletis JN, Makris F, Psichogiou M, Kostakis A, Hatzakis A. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Liver Transpl Surg. 1999;5(4):294–300.CrossRefGoogle Scholar
  14. 14.
    Althaf MM, Abdelsalam MS, Rashwan M, Nadri Q. Acute hepatitis C infection in a renal transplant recipient: primacy of the liver or kidney? BMJ Case Rep. 2014:6;2014.Google Scholar
  15. 15.
    Toth CM, Pascual M, Chung RT, Graeme-Cook F, Dienstag JL, Bhan AK, Cosimi AB. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation. 1998;66(9):1254–8.CrossRefGoogle Scholar
  16. 16.
    Delabaudière C, Lavayssière L, Dörr G, Muscari F, Danjoux M, Sallusto F, Peron JM, Bureau C, Rostaing L, Izopet J, Kamar N. Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation. Transpl Int. 2015;28(2):255–8.CrossRefGoogle Scholar
  17. 17.
    Wadhawan M, Vij V, Makki K, Bansal N, Kumar A. Early acute severe HCV recurrence after transplantation: from universal mortality to cure. J Clin Exp Hepatol. 2017;7(1):28–32.CrossRefGoogle Scholar
  18. 18.
    Li DL, Fang J, Zheng Z, Wu W, Wu Z. Successful treatment of fibrosing cholestatic hepatitis following kidney transplantation with allogeneic hematopoietic stem cell transplantation: a case report. Medicine. (Baltimore). 2015;94(5):e480.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2019

Authors and Affiliations

  1. 1.Department of Renal Surgery and TransplantationJichi Medical University HospitalShimotsukeJapan

Personalised recommendations